Stock Track | Viking Therapeutics (VKTX) Soars 5.79% as Phase 2b Trial Shows Promising Results for NASH Drug VK2809

Stock Track11-20 09:06

Viking Therapeutics (VKTX) stock surged 5.79% in the last 24 hours, driven by the positive results from the Phase 2b clinical trial of its drug candidate VK2809 for the treatment of non-alcoholic steatohepatitis (NASH).

The Phase 2b VOYAGE trial met both its primary and secondary endpoints, demonstrating statistically significant reductions in liver fat content at Week 12 and Week 52. Patients receiving VK2809 showed mean relative reductions in liver fat ranging from 37% to 55% at Week 52, with 64% to 88% of patients achieving at least a 30% reduction.

Importantly, VK2809 also showed impressive histologic results, with 63% to 75% of treated patients achieving NASH resolution without worsening of fibrosis, compared to 29% for placebo. Additionally, 44% to 57% of VK2809-treated patients demonstrated improvement in fibrosis without worsening of NASH, versus 34% for placebo. The drug demonstrated encouraging safety and tolerability, with the majority of treatment-related adverse events reported as mild or moderate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment